Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 3012-3017

  Triantafyllopoulou, Antigoni ^a   Franzke, Claus Werner ^a   Seshan, Surya V ^b   Perino, Giorgio ^a   Kalliolias, George D ^a   Ramanujam, Meera ^c   Van Rooijen, Nico ^d   Davidson, Anne ^c   Ivashkiv, Lionel B ^a,b,e  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

Alternative macrophages; Kidney disease; Polyinosinic: Polycytidylic acid; Systemic lupus erythematosus; Tissue repair

Indexed keywords

COLLAGEN TYPE 4; GROWTH FACTOR; INTERFERON; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GLOMERULONEPHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE I; INTERLEUKIN-10; LUPUS NEPHRITIS; LYMPHOKINES; MACROPHAGES; METALLOPROTEASES; MICE; MICE, INBRED NZB; OSTEOPONTIN; PLATELET-DERIVED GROWTH FACTOR; POLY I-C; PROTEINURIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC;

MURINAE; MUS;

EID: 77649267179     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914902107     Document Type: Article

References (36)

1. Schwartz MM, Korbet SM, Katz RS, Lewis EJ (2009) Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus 18:149-158.
2. Kojo S, et al. (2009) Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol 36:2218-2223.
3. Hill GS, et al. (2001) Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 59:304-316.
4. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN (2007) TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13:543-551.
5. Davidson A, Aranow C (2006) Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 18:468-475.
6. Baechler EC, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 4:2610-2615.
7. Kirou KA, et al. (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491-1503.
8. Jørgensen TN, Roper E, Thurman JM, Marrack P, Kotzin BL (2007) Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun 8:653-662.
9. Santiago-Raber ML, et al. (2003) Type-I interferon receptor deficiency reduces lupuslike disease in NZB mice. J Exp Med 197:777-788.
10. 1 but not in BALB/c mice. J Immunol 174:2499-2506.
11. Fairhurst AM, et al. (2008) Systemic IFN-α drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 38:1948-1960.
12. Ramanujam M, et al. (2009) Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 60:1096-1101.
13. Jørgensen TN, et al. (2006) Genetic susceptibility to polyI:C-induced IFNalpha/β-dependent accelerated disease in lupus-prone mice. Genes Immun 7:555-567.
14. Andrews BS, et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148:1198-1215.
15. Schiffer L, et al. (2008) Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 180:1938-1947.
16. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83-93.
17. Seshan SV, et al. (2009) Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114:1675-1683.
18. Tveita AA, Rekvig OP, Zykova SN (2008) Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int 74:1150-1158.
19. Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y (2002) Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant 17:1189-1196.
20. Zeisberg M, et al. (2006) Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3:e100.
21. Steinmann-Niggli K, Ziswiler R, Küng M, Marti HP (1998) Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 9:397-407.
22. Ronco P, Chatziantoniou C (2008) Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 74:873-878.
23. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629.
24. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
25. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969.
26. Liu Y, et al. (2008) Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 180:6270-6278.
27. Mori R, Shaw TJ, Martin P (2008) Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205:43-51.
28. Fairhurst AM, et al. (2009) Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 183:6831-6838.
29. Yoshimoto S, et al. (2007) Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis 50:47-58.
30. Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R (2006) FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 177:7287-7295.
31. Adalid-Peralta L, et al. (2008) Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. Kidney Int 73:172-180.
32. Tveita A, Rekvig OP, Zykova SN (2008) Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther 10:229.
33. Hudkins KL, et al. (2000) Osteopontin expression in human crescentic glomerulonephritis. Kidney Int 57:105-116.
34. Arnold L, et al. (2007) Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. 204:1057-1069.
35. Nahrendorf M, et al. (2007) The healingmyocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204:3037-3047.
36. Kurowska-Stolarska M, et al. (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183:6469-6477.